Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Lipid particle encapsulation
What ifWhat if the muscle-targeting agent sits on a lipid particle and the oligonucleotide is encapsulated inside the particle?
Claim language“covalently linked”
An ionizable lipid encapsulates the oligonucleotide, and a surface ligand binds a receptor on muscle cells. After receptor-mediated uptake, acidification protonates the lipid and promotes release of the oligonucleotide from the endosome.
1.1Local delivery with electroporation
What ifWhat if direct intramuscular injection and local electrical pulses deliver the oligonucleotide to muscle fibers?
Claim language“a muscle-targeting agent”
A needle deposits a buffered oligonucleotide solution in the muscle. Electrodes apply short pulses that transiently permeabilize nearby muscle fibers and increase entry of the oligonucleotide.
1.1Repression at the DNA promoter
What ifWhat if a guide RNA directs a transcriptional repressor to DUX4 promoter DNA?
Claim language“targeting a double homeobox 4 (DUX4) RNA”
A guide RNA pairs with promoter DNA and positions a catalytically inactive RNA-guided nuclease fused to a transcriptional repressor. The fusion protein reduces transcription from the promoter and lowers production of DUX4 RNA.
1.2Sixteen nucleotide antisense gapmer
What ifWhat if the antisense strand contains 16 nucleotides and recruits ribonuclease H?
Claim language“18-25 nucleotides in length”
A 16-nucleotide gapmer contains a central block of 10 DNA nucleotides flanked on each side by three affinity-enhancing modified nucleotides. The central block forms a DNA–RNA duplex with DUX4 RNA and recruits ribonuclease H to cleave the RNA.
1.1Binding through an affinity tag
What ifWhat if a binding pocket on the muscle-targeting protein holds a tagged oligonucleotide through reversible molecular recognition?
Claim language“covalently linked”
A terminal hapten on the oligonucleotide binds a hapten-binding domain fused to a muscle receptor-binding protein. The receptor internalizes the assembled complex, and an acid-sensitive binding domain releases the tagged oligonucleotide from the protein in the endosome.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Reagent for muscle assay calibration
A covalent muscle-targeting DUX4 oligonucleotide conjugate serves as a reference reagent for cell-based assay development. The assay uses differentiated skeletal muscle cells in multiwell plates with measurable DUX4 RNA. Each plate contains a dilution series of the reference conjugate, untreated wells, and wells treated with a conjugate carrying a non-targeting oligonucleotide. Measured DUX4 RNA levels across the dilution series establish the response range used to compare assay runs.
Component substitution
Single-stranded gapmer for DUX4 RNA
A 20-nucleotide gapmer replaces the RNA interference duplex and pairs with 20 consecutive nucleotides within a specified DUX4 target site. The gapmer has a 10-nucleotide DNA core flanked by two 5-nucleotide 2′-O-methoxyethyl wings. A terminal spacer covalently connects the gapmer to the muscle-targeting agent. After cellular uptake and hybridization, RNase H1 cleaves the RNA strand of the DNA–RNA hybrid.
Parameter or scale variation
Two duplexes per targeting antibody
A muscle-targeting antibody carries two copies of the same DUX4-targeting duplex at two engineered cysteines, one on each heavy chain. Each 21-nucleotide antisense strand contains a 19-nucleotide region complementary to a specified DUX4 target site. The sense strands carry terminal maleimide spacers that form covalent bonds with the cysteines. Intact mass spectrometry verifies the two-duplex loading, and cell assays compare one- and two-duplex conjugates at the same total antisense strand concentration.
Combination with existing systems
Perfused skeletal muscle tissue assay
A microfluidic tissue culture device houses a three-dimensional skeletal muscle construct derived from cells with measurable DUX4 expression. A pump delivers the covalent muscle-targeting conjugate through a channel adjacent to the construct, and a porous membrane permits exchange between the channel and the tissue compartment. Inlet and outlet samples track conjugate exposure during perfusion. Tissue collected after washout supplies the RNA for measurement of DUX4 and its downstream transcripts.
Automated or data-driven variant
Automated ranking of DUX4 conjugates
Software enumerates antisense strands from 18 to 25 nucleotides with at least 16 consecutive complementary positions within the specified DUX4 target sites. It filters candidates for predicted self-pairing and extended complementarity to other transcripts, then assigns the remaining sequences to wells. A liquid handler dispenses preassembled conjugates carrying the same muscle-targeting agent across a concentration series in differentiated muscle cells. Software fits the DUX4 RNA concentration-response curves and ranks candidates that meet a preset cell viability threshold.
Specific version of a part
Antibody fragment with amide linker
A receptor-binding antibody fragment recognizes an internalizing receptor on muscle cells. An amine at the 3′ end of the sense strand forms an amide bond with an activated carboxyl group on a spacer attached to the fragment.
Targeting peptide with thioether linkage
A muscle receptor-binding peptide carries a terminal cysteine. The cysteine thiol reacts with a haloacetyl group at the 3′ end of the sense strand to form a covalent thioether.
Twenty one nucleotide RNA duplex
A 21-nucleotide antisense strand pairs with a 21-nucleotide sense strand across 19 positions and creates a two-nucleotide 3′ overhang on each strand. The antisense strand contains 19 consecutive nucleotides complementary to a segment of SEQ ID NO: 200.
Twenty nucleotide antisense gapmer
A 20-nucleotide antisense strand contains a central block of 10 DNA nucleotides and five 2′-O-methoxyethyl nucleotides at each end. The strand pairs across all 20 positions with a segment of SEQ ID NO: 191, and the central DNA block recruits ribonuclease H.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a muscle-targeting agent covalently linked to an oligonucleotide targeting a double homeobox 4 (DUX4) RNA
The oligocation-oligonucleotide conjugate primer comprises an oligocation moiety covalently conjugated at 5′ end of an oligonucleotide sequence.
A · US 9,410,172 B2 · ¶ 1
1.2wherein the oligonucleotide comprises an antisense strand of 18-25 nucleotides in length and comprises a region of complementarity to a target sequence as set forth in SEQ ID NOs: 200, 191, 189, 186, 190, 174-185, 187, 188, 192-199, and 201-235, and wherein the region of complementarity is at least 16 consecutive nucleosides in length.
In some embodiments, the antisense strand is 19 to 21 nt in length (i.e., 19, 20 or 21 nt in length). In some embodiments, at least 13, 14, 15, 16, 17, 18, 19, 20 or 21 nt of the antisense strand are complementary to the tyrosinase mRNA sequence.
B · US 2017/0027837 A1 · ¶ 43
An empty cell means only that no passage was reproduced there.
Statements in these documents
Amplification of trace amounts of target DNA using conventional methods often results in incomplete amplification of DNA sequences leaving “dropouts” in sequence coverage and amplification bias wherein DNA sequences are amplified unevenly.
A · US 9,410,172 B2 · ¶ 4
Efficient methods for non-specifically amplifying trace amounts of target DNA are therefore highly desirable.
A · US 9,410,172 B2 · ¶ 4
Thus, there is a need for improved compositions and methods for the inhibition of melanin production and the treatment of skin pigmentation-related disorders, including melasma and age spots.
B · US 2017/0027837 A1 · ¶ 5
In certain aspects, provided herein are RNA complexes that inhibit tyrosinase and are useful for reducing melanin production and the treatment of pigmentation-related disorders, including melasma and age spots.
B · US 2017/0027837 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355336 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355336/, SHA-256 9905cbaf63bdd2ae3d12f13b81c4dc4fac243070fc327e174a5832f1129f2a01